Gilead Sciences Annual Meeting: Strong Shareholder Support for Management; Pipeline Growth and Acquisitions Highlighted
At Gilead Sciences' annual meeting on April 30, shareholders overwhelmingly supported management with high approval rates for director re-elections and executive pay. The company highlighted strong business momentum in 2025, including HIV sales of $20.8 billion led by Biktarvy, a robust clinical pipeline, recent acquisitions, and upcoming product launches.
Topics: acquisitions corporate governance dividends executive pay pipeline stock buybacks